IFEMA Convention Center - Feria de Madrid, Warsaw Hall, Avda. del Partenón, 5, 28042 Madrid, Spain
Helmsley’s Type 1 Diabetes Program will host a one-day industry session on the occasion of the 60th Annual Meeting of the European Association for the Study of Diabetes.
Join us for this scientific meeting exploring the latest research in how alpha and delta cell dysfunction leads to hypoglycemia, and efforts to therapeutically restore the body’s ability to reverse it. Session themes will include:
Note that this meeting is intended to focus on islet biology and the physiological response to hypoglycemia and not, for example, on automated insulin delivery, novel insulins, or beta cell replacement.
Sebastian Barg, PhD, Uppsala University, Sweden
Joan Camuñas-Soler, PhD, University of Gothenburg, Sweden
Malin Fex, PhD, Lund University, Sweden
Rui Gao, MBBS, PhD, University of Oxford, England
Karen Hauda, JD, MS, Novo Nordisk, United States
Richard Liggins, PhD, Zucara Therapeutics, Canada
Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte, Denmark
Marjana Marinac, PharmD, Breakthrough T1D, United States
Dale Morrison, PhD, University of Melbourne, Australia
Alvin C. Powers, MD, Vanderbilt University, United States
Michael Rickels, MD, MS, University of Pennsylvania School of Medicine, United States
Lori Sussel, PhD, University of Colorado Anschutz Medical Campus, United States
Quan Zhang, PhD, University of Oxford, England and University of Coimbra, Portugal
Marcela Brissova, PhD, Vanderbilt University Medical Center, United States
Shareen Forbes, MBChB, PhD, FRCP, University of Edinburgh, Scotland
Patrick Gilon, PhD, Université Catholique de Louvain, Belgium
Philippe Lysy, MD, PhD, Université Catholique de Louvain, Belgium
David Piston, PhD, Washington University in St. Louis, United States
Patrik Rorsman, PhD, Oxford University, England
Jason Winnick, PhD, University of Cincinnati, United States
Gina Yosten, PhD, St. Louis University School of Medicine, United States
Conchi Izquierdo, PhD, Helmsley Charitable Trust, United States
Ben Williams, PhD, Helmsley Charitable Trust, United States
Advance registration requested
We encourage those interested in attending to register in advance. Note that in-person admission will be on a first-come, first-served basis, and registration is required to attend the Helmsley session lunch. Virtual participation will be available for those unable to attend in-person.
Note that separate registration for the EASD meeting is also required to attend. If you would like to register only for the one-day industry session, please email exh_reg_easd@interplan.de for more information.
Read more about our poster abstracts (PDF)
Read more about our speakers (PDF)
Welcome / Introduction
Ben Williams, PhD, Helmsley Charitable Trust, United States
Alvin C. Powers, MD, Vanderbilt University, United States
Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes
Session Chair: Gina Yosten, PhD, St. Louis University School of Medicine, United States
9:15-9:45 AM Lori Sussel, PhD, University of Colorado Anschutz Medical Campus, United States. Alphabet(a) soup: Unraveling cell fate decisions in the islet
9:45-9:55 AM Q&A
10:00-10:30 AM Joan Camuñas-Soler, PhD, University of Gothenburg, Sweden. Cell Dysfunction in diabetes: insights from single-cell studies
10:30-10:40 AM Q&A
Break: Snacks and coffee
Short talks from submitted abstracts
Session Chair: Jason Winnick, PhD, University of Cincinnati, United States
11:00-11:15 AM Malin Fex, PhD, Lund University, Sweden. Loss of the melatonin receptor type 1 (Mt1) results in dysregulated α-cell function and metabolism
11:15-11:20 AM Q&A
11:20 -11:35 AM Sebastian Barg, PhD, Uppsala University, Sweden. Resistance to para- and autocrine inhibition causes hypersecretion of somatostatin in single δ-cells of human diabetic donors
11:35 -11:40 AM Q&A
11:40 -11:55 AM Rui Gao, MBBS, PhD, University of Oxford England. Disruption of electrical coupling between β- and δ-cells results in impaired glucagon response to hypoglycemia in type 1 diabetes.
11:55-12:00 PM Q&A
Lunch
Understanding and restoring alpha cell function in T1D and T2D: Intrinsic, paracrine, and in vivo consequences in humans
Session Chair: Shareen Forbes, MBChB, PhD, FRCP, University of Edinburgh, Scotland
1:00-1:15 AM Dale Morrison, PhD, University of Melbourne, Australia. Glucoregulatory impact of whey protein ingestion in adults with type 1 diabetes
1:15-1:20 AM Q&A
1:20 -1:35 AM Quan Zhang, PhD, University of Oxford and University of Coimbra, Portugal. Hypoglycemia sensitises negative feedback control of glucagon secretion underlies defective glucagon response in recurrent hypoglycemia
11:35 -11:40 AM Q&A
1:45-2:15 PM Michael Rickels, MD, MS, University of Pennsylvania School of Medicine, United States. Understanding and restoring alpha cell function in type 1 diabetes
2:15-2:25 PM Q&A
Break: Snacks and coffee
Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia
Session Chair: Marjana Marinac, PharmD, Breakthrough T1D, United States
2:50-3:00 PM Marjana Marinac, PharmD, Breakthrough T1D, United States. Outcomes beyond A1c and the patient perspective
3:05-3:15 PM Karen Hauda, JD, MS, Novo Nordisk, United States. Impact of health authority regulations on clinical development
3:20-3:30 PM Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte, Denmark. Clinical trial designs to identify hypoglycemic prevention candidates – considerations and challenges
3:30-3:40 PM Richard Liggins, PhD, Zucara Therapeutics, Canada. ZT-01, a somatostatin receptor 2 antagonist targets the a cell to restore glucagon counterregulation and prevent hypoglycemia: a Phase 1 and 2 clinical update
3:40-4:30 PM Discussion Session
Karen Hauda, JD, MS, Novo Nordisk, United States
Richard Liggins, PhD, Zucara Therapeutics, Canada
Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte, Denmark
Closing Remarks
Conchi Izquierdo, PhD, Helmsley Charitable Trust, United States
Ben Williams, PhD, Helmsley Charitable Trust, United States
Poster Session
This session will be held at the IFEMA Convention Center – Feria de Madrid, Warsaw Hall, Avda. del Partenón, 5, 28042 Madrid, Spain.
The floorplan for the IFEMA Convention Center – Feria de Madrid can be found here under “Venue & Travel”.
Please contact hypoglycemia@helmsleytrust.org.
The Type 1 Diabetes (T1D) program is dedicated to helping the global T1D community live safer, better, and more fulfilling lives today while funding advancements in research and technology for a better tomorrow.